Two Tumors, One Target: Preliminary Experience With 90Y-FAPI Therapy in a Patient With Metastasized Breast and Colorectal Cancer.
| Autor: | Rathke H; From the Department of Nuclear Medicine, Heidelberg University Hospital., Fuxius S; Practice for Oncology, Heidelberg., Giesel FL, Lindner T; From the Department of Nuclear Medicine, Heidelberg University Hospital., Debus J; Department of Radiation Oncology, Heidelberg University Hospital., Haberkorn U, Kratochwil C; From the Department of Nuclear Medicine, Heidelberg University Hospital. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical nuclear medicine [Clin Nucl Med] 2021 Oct 01; Vol. 46 (10), pp. 842-844. |
| DOI: | 10.1097/RLU.0000000000003842 |
| Abstrakt: | Abstract: We report a patient with breast cancer (BC) diagnosed in 2009 with metachronous lymph node, liver, and bone metastases. In 2017, colorectal cancer with peritoneal metastases was additionally diagnosed and treated with 8 cycles of capecitabine due to its antitumor activity against both malignancies. At progression of both diseases, FAPI PET/CT demonstrated positive tumor targeting in BC-related metastases and colorectal cancer-related metastases. The patient received an experimental therapy with 90Y-FAPI46. Although there was similar tracer uptake in the PET/CT, the radioligand therapy resulted in mixed response with disappearance of peritoneal metastases but minor efficacy treating the BC-related metastases. Competing Interests: Conflicts of interest and sources of funding: T.L., U.H., C.K., and F.L.G. have a patent application for FAPI ligands. T.L., U.H., C.K., and F.L.G. also hold shares of a consultancy for iTheranostics. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|